Popular GLP-1 Weight-Loss Drugs Linked to Potentially Deadly Brain Disorder
Researchers Warn of Rare but Serious Brain Condition
Researchers are warning about a rare but potentially life-threatening brain condition that may be linked to popular GLP-1 weight-loss medications.
A new study, published in Clinical Nutrition, has identified 15 reported cases of Wernicke encephalopathy—a neurological disorder caused by severe vitamin B1 deficiency—in individuals taking GLP-1 receptor agonists.
Most of the reported cases involved semaglutide, sold under the brand names Ozempic and Wegovy, or tirzepatide, marketed as Mounjaro and Zepbound.
Doctors found these cases through the FDA’s Adverse Event Reporting System (FAERS), published medical literature, and their own medical center. Most patients reported gastrointestinal symptoms or nutritional issues, including:
- Weight loss
- Vomiting
- Loss of appetite
- Malnutrition
The researchers emphasized that while reports of the disorder appeared more frequently among those taking GLP-1 medications, the study cannot prove a causal relationship.
